Ira Gantz - Researcher Profile | RDL Research Database

Publications

2 shown

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes

Darren K. McGuire , Weichung Shih , Francesco Cosentino +11 more

In this meta-analysis, SGLT2 inhibitors were associated with a reduced risk of major adverse CV events; in addition, results suggest significant heterogeneity in associations wi...

2020 JAMA Cardiology 1070 citations

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Christopher P. Cannon , Richard E. Pratley , Samuel Dagogo‐Jack +12 more

Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Fu...

2020 New England Journal of Medicine 1396 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 2,466
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)

External Links

Google Scholar

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.

Publications

Frequent Co-Authors

Researcher Info

External Links

Impact Metrics

Academic Output Over Time